$4.13
-0.12 (-2.82%)
Open$4.25
Previous Close$4.25
Day High$4.25
Day Low$4.01
52W High$7.12
52W Low$3.22
Volume—
Avg Volume297.9K
Market Cap120.64M
P/E Ratio—
EPS$-1.57
SectorBiotechnology
Analyst Ratings
Strong Buy
11 analysts
Price Target
+738.0% upside
Current
$4.13
$4.13
Target
$34.61
$34.61
$23.82
$34.61 avg
$34.97
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 77.72M | 60.88M | 25.19M |
| Net Income | -52,729,862 | -37,174,428 | -2,467,246 |
| Profit Margin | -67.9% | -64.5% | -9.8% |
| EBITDA | -43,613,483 | -32,455,592 | -4,050,890 |
| Free Cash Flow | — | — | -1,532,934 |
| Rev Growth | +27.7% | +27.7% | +20.8% |
| Debt/Equity | 9.39 | 9.39 | 0.40 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $251.64 | -1.05% | 118.2 | 429.58B |
| AMGN | Amgen Inc | $362.12 | +0.44% | 24.8 | 193.10B |
| GILD | Gilead Sciences Inc | $126.34 | +0.01% | 17.1 | 157.21B |
| VRTX | Vertex Pharmaceuticals Inc | $496.73 | -0.58% | 28.1 | 121.87B |
| REGN | Regeneron Pharmaceuticals | $623.54 | -1.31% | 15.0 | 66.35B |
| ALNY | Alnylam Pharmaceuticals Inc | $301.03 | +2.56% | 69.3 | 39.97B |